Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, both in adjuvant and metastatic settings.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable global distribution to hospitals, pharmacies and cancer treatment facilities.

Letrozole is used in endocrine therapy for hormone‑dependent breast cancer.

- Adjuvant treatment of hormone receptor‑positive breast cancer in postmenopausal women: reduces risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer in postmenopausal women: helps control tumor progression and prolongs survival. - Estrogen‑dependent breast cancer in postmenopausal patients: provides systemic endocrine inhibition of estrogen production.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: arthralgia and myalgia. - Fatigue: persistent tiredness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases, jaundice. - Bone fracture: increased risk of osteoporosis‑related fractures. - Allergic reaction: rash, angioedema, or anaphylaxis.

When prescribing Letrozole, clinicians should observe several precautionary measures to ensure patient safety.

- Assess bone health: monitor bone mineral density and consider calcium/vitamin D supplementation. - Evaluate liver function: avoid use in patients with severe hepatic impairment. - Monitor cardiovascular status: be alert for thromboembolic events, especially in high‑risk individuals. - Contraindicated in pregnancy: category X, must not be used in pregnant women. - Store at ambient temperature: keep in original container, protect from moisture and light.

Letrozole can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes Letrozole’s aromatase inhibition, reducing therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower Letrozole plasma concentrations. - Tamoxifen: opposing mechanisms may diminish efficacy of both agents.

Moderate Interactions (Monitor Closely): - Warfarin: Letrozole may increase INR, requiring more frequent coagulation monitoring. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect Letrozole metabolism, monitor for side‑effect changes.